https://www.selleckchem.com/products/at-406.html
Importantly, targeting MYBL2, or treatment with either the YAP/TAZ inhibitor Verteporfin or the RhoA inhibitor Simvastatin, reversed the resistance to ADT and blocked bone metastasis in CRPC cells. Finally, high MYBL2 levels were positively associated with TNM stage, total PSA level, and Gleason score and predicted a higher risk of metastatic relapse and poor prognosis in patients with PCa. Conclusions Our results reveal a novel molecular mechanism conferring resistance to ADT and provide a strong rationale for potential therapeutic stra
Like
Comment
Share
